TICKERNERD
Menu
SLSSLSHealthcare · Biotechnology

SLS Stock Forecast: SELLAS Life Sciences Group, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$12
−4.27% on the day

The 2 Wall Street analysts covering SELLAS Life Sciences Group, Inc. hold a median 12-month price target of $33 — +173.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 13 Oct 2026 — in the upper half.

Market cap
$2.5B
Ticker Nerd rank
60 / 100
Median analyst target
$33
Analysts covering
2
Revenue$0.0
Operating income−$10.6M
Net income−$9.6M
Free cash flow−$7.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.0%
1M
+1.3%
YTD
+215.1%
1Y
+479.5%
From 52W high
−23.2%
From 52W low
+754.7%
$1
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SLS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SELLAS Life Sciences Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Value
93
Quality
78
Revisions
64
Growth
33
Size
32
Accruals
29
Volatility
27
Issuance
27

Momentum (98): The shares have been drifting up relative to others.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SLS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26SLSHigh $35Median $33Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $30Median $33High $35

The green dot is the last close — the median target sits +173.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Mar 2026Maxim GroupMaintainsBuy$7.00 → $10
12 Mar 2026Maxim GroupMaintainsBuy—
16 July 2025Maxim GroupMaintainsBuy—
22 Nov 2023Cantor FitzgeraldReiteratesOverweight—
7 Sept 2023Cantor FitzgeraldReiteratesOverweight—
15 Nov 2022Alliance Global PartnersMaintainsBuy—
28 June 2022Cantor FitzgeraldMaintainsOverweight—
21 July 2021Cantor FitzgeraldInitiatesOverweight—
18 Nov 2019Alliance Global PartnersInitiatesBuy—
18 Nov 2019H.C. WainwrightInitiatesBuy—
18 Nov 2019Maxim GroupUpgradeBuy—
18 Nov 2019OppenheimerInitiatesOutperform—
15 Nov 2019Maxim GroupUpgradeBuy—
8 Apr 2019Alliance Global PartnersInitiatesBuy—
1 Nov 2018OppenheimerInitiatesOutperform—
20 July 2018Maxim GroupMaintainsBuy—
2 Apr 2018H.C. WainwrightInitiatesBuy—
2 Apr 2018HC Wainwright & Co.InitiatesBuy—
19 Mar 2018Maxim GroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SLS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, SELLAS Life Sciences Group, Inc. returned +479.5% against +17.5% for the S&P 500, dividends included.

SLS vs S&P 500, last 12 monthsTotal return, rebased to 100
0200400600800Jan 26Apr 26Jul 26Oct 26SLSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SLS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

SELLAS Life Sciences Group, Inc. (SLS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−49.6×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
18.2×

Cheaper than 6% of US stocks

EV / EBITDA
−83.8×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−39.6%

Higher than 24% of US stocks

Return on assets
−23.3%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SELLAS Life Sciences Group, Inc. (SLS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SELLAS Life Sciences Group, Inc. has a market value of $2.5B and an enterprise value of $2.4B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$32.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$28.4M.

  • Shares outstanding: 201.9M.

  • Trailing P/E: −49.6×; forward P/E: −124.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • SELLAS Life Sciences Group, Inc. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

SLS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SLSSELLAS Life Sciences Group, Inc.$2.5B
60
BEAMBeam Therapeutics, Inc.$2.5B
46
PGENPrecigen, Inc.$2.6B
82
MBXMBX Biosciences, Inc.$2.3B
36
NAMSNewAmsterdam Pharma Co. NV$2.3B
39
ADMAADMA Biologics, Inc.$2.3B
49
RCUSArcus Biosciences, Inc.$2.8B
59

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SELLAS Life Sciences Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SLS news & analysis

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

GlobeNewsWire · 25 Sept 2026positive

SELLAS Life Sciences announced preclinical data from studies evaluating its CDK9 inhibitor SLS009 (tambiciclib) in patient-derived organoid models of pancreatic ductal adenocarcinoma. The findings are being presented at the AACR Conference on Pancreatic Cancer in San Diego, September 25–28, 2026.

Why it matters — The new preclinical findings could indicate broader potential for SLS009 beyond its currently studied indications, expanding its pipeline opportunity in pancreatic cancer.

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

GlobeNewsWire · 2 Sept 2026positive

SELLAS Life Sciences announced that three abstracts evaluating SLS009 (tambiciclib), a selective CDK9 inhibitor, in preclinical models of pancreatic ductal adenocarcinoma (PDAC) have been accepted for poster presentation at the 2026 AACR Conference on Pancreatic Cancer. The studies were conducted in collaboration with the University of Wisconsin School of Medicine and Public Health and will highlight preclinical activity across patient-derived KRAS mutant organoid models.

Why it matters — For SLS watchers, this expands the potential application of SLS009 beyond its current focus and signals progress in preclinical research for pancreatic cancer, a difficult-to-treat indication.

When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges

Benzinga · 27 Aug 2026positive

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) stock is trading higher on Thursday, with the shares having surged around 300% year-to-date. The report notes this follows a US Food and Drug Administration win by another company, Revolution Medicines, which lifted sentiment for other biotech stocks.

Why it matters — An SLS watcher would care because the stock's sharp rise and its link to a broader biotech sector boost reflect notable market attention on the company's recent performance.

This One Data Readout Could Make Or Break Sellas Life Sciences Group

Seeking Alpha · 13 Aug 2026positive

The article discusses the pivotal Phase 3 REGAL trial readout for SELLAS Life Sciences Group's GPS in acute myeloid leukemia, noting the unusually long trial timeline and the company's $138.3 million cash position with funding targeted into 2027.

Why it matters — SLS watchers would care because the Phase 3 REGAL readout for GPS in AML is a key catalyst that could materially affect the company's outlook, while its cash position is described as supporting operations into 2027.

FAQ

Frequently asked questions about SLS stock

What is the SLS stock price forecast for 2026-2027?

The 2 Wall Street analysts covering SELLAS Life Sciences Group, Inc. have a median 12-month price target of $33, with estimates ranging from $30 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SLS stock a buy right now?

Of the 2 analysts covering SELLAS Life Sciences Group, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SELLAS Life Sciences Group, Inc. 60 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SLS?

As at 13 Oct 2026, SELLAS Life Sciences Group, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will SLS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +173.6% from the last close, and Ticker Nerd's factor model ranks SELLAS Life Sciences Group, Inc. 60 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SLS stock forecast for 2030?

No analyst covering SELLAS Life Sciences Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $35 over the next 12 months.

How has SLS stock performed over the past year?

SELLAS Life Sciences Group, Inc. returned +479.5% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SELLAS Life Sciences Group, Inc. do?

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for cancer.

What is the latest news on SLS?

The most recent item we track (GlobeNewsWire, 25 Sept 2026): "SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer". SELLAS Life Sciences announced preclinical data from studies evaluating its CDK9 inhibitor SLS009 (tambiciclib) in patient-derived organoid models of pancreatic ductal adenocarcinoma. The findings are being presented at the AACR Conference on Pancreatic Cancer in San Diego, September 25–28, 2026.

Company

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for cancer. SELLAS Life Sciences Group, Inc. concentrates on immunotherapeutic and targeted oncology programs designed to address a broad range of hematologic and solid tumor indications. Its current pipeline includes product candidates aimed at cancers such as acute myeloid leukemia, reflecting its emphasis on disease areas with significant unmet medical need. The company’s work centers on advancing clinical-stage assets through research and development, with a business model built around innovative cancer treatment platforms rather than commercialized consumer products. Headquartered in New York, SELLAS Life Sciences Group, Inc. plays a role in the biotechnology market as a specialist developer of experimental oncology therapies.

CEO Dr. Angelos M. Stergiou M.D., ScD h.c. · 13 employees · United States · https://sellaslifesciences.com